Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Kessler

Showing results (81-90 of 145) with videos related to

Pageof 15
Sort By:
The American Journal of Cardiology|December 13, 2000
Both atenolol and propranolol blunt the fibrinolytic response to exercise but not resting fibrinolytic potentialB Fernhall, L M Szymanski, P A Gorman, et al.
Blood|July 15, 1995
A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulinR S Schwartz, D A Gabriel, L M Aledort, et al.
British Journal of Haematology|January 1, 1985
IgA inhibitor to factor VIII/von Willebrand factorH R Gralnick, M A Flaum, C M Kessler, et al.
Thrombosis and Haemostasis|May 1, 1995
Catalyzing global access to hemophilia careC M Kessler, G A Gellert, G Mariani, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 9, 2011
Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008)E J Neufeld, C M Kessler, J C Gill, et al.
American Journal of Hematology|September 1, 1991
Skin necrosis following prolonged administration of coumarin in a patient with inherited protein S deficiencyS L Goldberg, C L Orthner, B L Yalisove, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 18, 2015
Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatmentS R Earnshaw, C N Graham, C L McDade, et al.
JAMA|June 16, 1989
The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapyG F Pierce, J M Lusher, A P Brownstein, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 2, 2002
Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIIIP L F Giangrande, C M Kessler, C E Jenkins, et al.
American Journal of Obstetrics and Gynecology|October 16, 1999
Hemostatic responses to maximal exercise in oral contraceptive usersR Otterstetter, L M Szymanski, G H Kamimori, et al.
Pageof 15

Showing results (81-90 of 145) with videos related to

Sort By:
Pageof 15
The American Journal of Cardiology|December 13, 2000
Both atenolol and propranolol blunt the fibrinolytic response to exercise but not resting fibrinolytic potentialB Fernhall, L M Szymanski, P A Gorman, et al.
Blood|July 15, 1995
A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulinR S Schwartz, D A Gabriel, L M Aledort, et al.
British Journal of Haematology|January 1, 1985
IgA inhibitor to factor VIII/von Willebrand factorH R Gralnick, M A Flaum, C M Kessler, et al.
Thrombosis and Haemostasis|May 1, 1995
Catalyzing global access to hemophilia careC M Kessler, G A Gellert, G Mariani, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 9, 2011
Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008)E J Neufeld, C M Kessler, J C Gill, et al.
American Journal of Hematology|September 1, 1991
Skin necrosis following prolonged administration of coumarin in a patient with inherited protein S deficiencyS L Goldberg, C L Orthner, B L Yalisove, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 18, 2015
Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatmentS R Earnshaw, C N Graham, C L McDade, et al.
JAMA|June 16, 1989
The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapyG F Pierce, J M Lusher, A P Brownstein, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 2, 2002
Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIIIP L F Giangrande, C M Kessler, C E Jenkins, et al.
American Journal of Obstetrics and Gynecology|October 16, 1999
Hemostatic responses to maximal exercise in oral contraceptive usersR Otterstetter, L M Szymanski, G H Kamimori, et al.
Pageof 15